From: Treatment, outcomes, and demographics in sinonasal sarcoma: a systematic review of the literature
Tumor Type | n | % |
---|---|---|
Alveolar soft part sarcoma | 1 | 0.5% |
Angiosarcoma | 4 | 2.0% |
Carcinosarcoma | 2 | 1.0% |
Chondrosarcoma | 16 | 8.1% |
Ewing’s sarcoma | 56 | 28.3% |
Fibrosarcoma | 5 | 2.5% |
Granulocytic sarcoma | 5 | 2.5% |
Interdigitating dendritic cell sarcoma | 1 | 0.5% |
Leiomyosarcoma | 12 | 6.1% |
Liposarcoma | 2 | 1.0% |
Low grade sinonasal sarcoma with neural and myogenic features | 2 | 1.0% |
Myofibroblastic sarcoma | 2 | 1.0% |
Myxofibrosarcoma | 3 | 1.5% |
Neurofibrosarcoma | 1 | 0.5% |
Neurosarcoma | 1 | 0.5% |
Osteosarcoma | 11 | 5.6% |
Peripheral neuroectodermal tumor (PNET) | 14 | 7.1% |
Rhabdomyosarcoma | 14 | 7.1% |
Sarcomatoid sarcoma | 1 | 0.5% |
Synovial sarcoma | 2 | 1.0% |
Teratocarcinosarcoma | 14 | 7.1% |
Teratosarcoma | 1 | 0.5% |
Triton tumor (malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation) | 2 | 1.0% |
Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH) | 25 | 12.6% |